Stanton R. Mehr

The cost-saving potential of specialty or disease-specific ACOs can be huge...but it is unclear whether these specialty services are more efficiently provided through their own ACO or as ancillary to the burgeoning primary care ACO marketplace.

Value-Based Contracting for Pharmaceuticals: Getting Ready for Prime Time?

ByStanton R. Mehr

May 7th 2013

Is There a Business Case for Diabetes Disease Management?

ByStanton R. Mehr

April 11th 2013

The Complexity of Covering Off-Label Use for a Multitude of Oncology Regimens

ByStanton R. Mehr

December 7th 2012

Latest Updated Articles

The Intestinal Bug Hypothesis in Crohn's Disease Gets a Reboot
Published: October 21st 2014 | Updated:
The Economic Costs of Crohn's Disease
Published: October 21st 2014 | Updated:
Increasing Access to HIV Care May Help Improve Outcomes
Published: April 22nd 2014 | Updated:
Exploring the Intersection of Chronic Disease, Adherence, and Life Expectancy
Published: October 14th 2014 | Updated:
Targeted Products Yield Most Promising Results
Published: March 12th 2012 | Updated:
Chronic Myelogenous Leukemia
Published: May 23rd 2012 | Updated:

Stanton R. Mehr

Articles by Stanton R. Mehr

The Intestinal Bug Hypothesis in Crohn's Disease Gets a Reboot

The Economic Costs of Crohn's Disease

Exploring the Intersection of Chronic Disease, Adherence, and Life Expectancy

Recurrence of Breast Cancer Years After the Initial Tumor

Upending of Conventional Combination Therapy in Type 2 Diabetes Mellitus

Breast Cancer Survivorship Programs: More Than a Treatment

Robotic-Assisted Surgery: A Question of Value

Can Gastric Bypass Surgery Be a Cure for Diabetes Mellitus?

Inhaled Insulin's Long Journey to Commercialization

A Patient's Opinion of Unmet Need

The How and Why of Stress, Diabetes, and the Brain

Increasing Access to HIV Care May Help Improve Outcomes

Targeted Programmed Cell Death in Lung Cancer Treatment

The Link Between a Common Type of Bariatric Surgery and Increased Alcohol Use

The Continuing Evolution of Employer-Based Intervention in Diabetes Disease Management

What Is the Place of New SGLT-2 Inhibitors in Therapy and on the Formulary?

Is Medicare Ready for Oncology Clinical Pathways?

Attacking Complications to Kidney Problems in Diabetes: Atrial Fibrillation and Resistant Hypertension

Nonincretin Drugs in Later-Stage Development

New Approaches to Medicaid Expansion: Hybrid Plans Offer Alternatives for Covering More People

The Next Frontier for the Artificial Pancreas: Payer Coverage

Sequester Forcing Chemo Treatments into Hospitals Costing Taxpayers More in the End

BMI and Beyond: Identifing Obesity in Patients at Risk for Diabetes and Heart Disease

Innovations on the Horizon for the Treatment of Type 2 Diabetes An Interview With Javier Morales, MD

Searching for Clinical and Economic Value in Pancreatic Cancer

Chemoprevention in Prostate Cancer: Identifying Patients at Greatest Risk May Provide Greatest Value

Applying Accountable Care to Oncology: Developing an Oncology ACO

Value-Based Contracting for Pharmaceuticals: Getting Ready for Prime Time?

Is There a Business Case for Diabetes Disease Management?

The Complexity of Covering Off-Label Use for a Multitude of Oncology Regimens

Latest Updated Articles

Trending on AJMC

Promises and Pitfalls of AI in Health Care

Paul Ryan Champions Health Care Policy Reform, AI Amid Government Shutdown

Zanubrutinib Safe, Effective in Real-World CLL/SLL Cohort

Review Outlines Shared Pathways Between CKD, VHD

Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing